UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for endometrial cancer in the United Kingdom. Explore treatment pathways including immunotherapy and targeted therapy.
Endometrial cancer affects ~9,700 women per year in the UK and is the most common gynaecological cancer. Incidence is rising, partly due to increasing obesity. Most cases (75-80%) are diagnosed at an early stage with good prognosis. The TCGA molecular classification system (POLE ultra-mutated, MSI-H, copy-number high, copy-number low) guides treatment decisions.
Early stage: surgery (hysterectomy ± lymph node removal). Advanced or recurrent: immunotherapy has transformed treatment - dostarlimab + carboplatin is now standard first-line for advanced disease. For MSI-H tumours (~25-30%), immunotherapy alone (pembrolizumab or dostarlimab) can be remarkably effective. Other options include hormonal therapy (progestins) for low-grade tumours, and combinations of immunotherapy with targeted agents like lenvatinib.
Active UK trials include: novel immunotherapy combinations, antibody-drug conjugates targeting HER2 (for serous carcinoma), PARP inhibitor combinations, and fertility-preserving approaches for young women. The POLE/MSI biomarker-driven approach is opening new precision medicine trials.
Free AI-powered matching - no signup required
Search womb cancer Trials →